Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
Viral N Shah, Edward Franek, Karin Wernicke-Panten, Suzanne Pierre, Bhaswati Mukherjee, Karita Sadeharju, Viral N Shah, Edward Franek, Karin Wernicke-Panten, Suzanne Pierre, Bhaswati Mukherjee, Karita Sadeharju
Abstract
Introduction: The biosimilar SAR341402 insulin aspart (SAR-Asp) was compared to its originator NovoLog®/NovoRapid® insulin aspart (NN-Asp) in terms of efficacy, safety, and immunogenicity, in adults with type 1 or type 2 diabetes switching from different rapid-acting insulin analogs.
Methods: This phase 3, randomized, open-label, multinational, 52-week study (GEMELLI 1) enrolled participants with type 1 or type 2 diabetes (n = 597). At randomization, participants transitioned from NovoLog/NovoRapid (n = 380) or Humalog®/Liprolog® (n = 217) to equivalent (1:1) doses (or a dose at the discretion of the investigator) of either SAR-Asp or NN-Asp (1:1 randomization). Participants were treated with multiple daily injections in combination with insulin glargine 100 U/mL (Lantus®). In this subgroup analysis, efficacy measures (change in hemoglobin A1c [HbA1c], insulin dose [total, basal and mealtime]), and safety outcomes (hypoglycemia incidence, adverse events, anti-insulin aspart antibodies) of SAR-Asp were compared with those of NN-Asp separately according to the participants' prestudy mealtime insulin.
Results: At week 26 (primary efficacy endpoint), change in HbA1c was similar between SAR-Asp and NN-Asp in those participants pre-treated with NovoLog/NovoRapid (least squares [LS] mean difference - 0.04%, 95% confidence interval [CI] - 0.182 to 0.106%) or Humalog/Liprolog (LS mean difference - 0.15%, 95% CI - 0.336 to 0.043%) (P value for treatment by subgroup interaction = 0.36). This HbA1c response persisted over the 52 weeks of the study similarly for both treatments within each subgroup. In both subgroups, changes in insulin doses were similar between treatments over 26 weeks and 52 weeks, as were the incidences of severe or any hypoglycemia, adverse events (including hypersensitivity and injection site reactions), and anti-insulin aspart antibodies.
Conclusions: Efficacy and safety (including immunogenicity) profiles of SAR-Asp are similar to those of NN-Asp over 52 weeks in adults with diabetes irrespective of prior type of mealtime insulin.
Trial registration: ClinicalTrials.gov identifier: NCT03211858.
Keywords: Biosimilar insulin; GEMELLI 1; Insulin aspart; SAR341402; Subgroup by prior mealtime insulin.
Figures
References
- Novo Nordisk. NovoLog, insulin aspart injection 100 units/mL, NovoNordisk. Prescribing information, revised: 11/2019. . Accessed 9 Sept 2020.
- European Medicines Agency. NovoRapid. Summary of product characteristics, 23 August 2019. Accessed 9 Sept 2020.
- Hermansen K, Bohl M, Schioldan AG. Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs. 2016;76:41–74. doi: 10.1007/s40265-015-0500-0.
- European Medicines Agency. Insulin aspart Sanofi. Summary of product characteristics, 7 July 2020. Accessed 9 Sept 2020.
- Kapitza C, Nosek L, Schmider W, Teichert L, Nowotny I. Single-dose euglycemic clamp study demonstrating pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and US- and EU-approved versions of insulin aspart in subjects with type 1 diabetes. Diabetes Technol Ther. 2020;22:278–284. doi: 10.1089/dia.2019.0351.
- Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: a randomized open-label trial (GEMELLI 1) Diabetes Technol Ther. 2020;22:85–95. doi: 10.1089/dia.2019.0382.
- Garg SK, Wernicke-Panten K, Wardecki M, et al. Safety, immunogenicity, and glycemic control of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes also using insulin glargine: 12-month results from the GEMELLI 1 trial. Diabetes Technol Ther. 2020;22:516–526. doi: 10.1089/dia.2020.0008.
- Thrasher J, Polsky S, Hovsepian L, et al. Safety and tolerability of insulin aspart biosimilar SAR341402 versus originator insulin aspart (NovoLog) when used in insulin pumps in adults with type 1 diabetes: a randomized, open-label clinical trial. Diabetes Technol Ther. 2020;22:666–673. doi: 10.1089/dia.2019.0446.
- Eli Lilly and Company. Humalog (insulin lispro injection) [package insert]. Eli Lilly and Company, 11/2019. Accessed 9 Sept 2020.
- European Medicines Agency. Humalog. Summary of product characteristics, 10 February 2020. . Accessed 9 Sept 2020.
- European Medicines Agency. Liprolog. Summary of product characteristics, 11 February 2020. Accessed 9 Sept 2020.
- Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069. doi: 10.1016/S0140-6736(00)02039-0.
- Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them! Curr Control Trials Cardiovasc Med. 2000;1:25–27. doi: 10.1186/CVM-1-1-025.
Source: PubMed